

Index

A

ABCDEs of melanoma, 10, 24
Acral lentiginous melanoma (ALM), 15, 16, 32, 33, 116
Adjuvant testing, 29
Advanced stage disease, 106
AJCC 2018 guidelines, 54
Allogeneic hematopoietic stem-cell transplant recipients, 20
Amelanotic melanoma, 33, 73
American Joint Commission on Cancer (AJCC) staging system, 150, 167
American Society of Clinical Oncology (ASCO), 127
Angiomatoid melanoma, 38
Angiotropism, 74
Antimony sulfide colloid, 88
Anti-PD-1 therapy, 158
Atezolizumab, 47
Atypical Spitz tumor, 30, 32
Avelumab, 47
Axillary dissection, 154
Axillary lymph nodes, 120
Axillary lymphadenectomy, 164

B

Bacillus Calmette-Guerin (BCG) Injection, 117, 118
Balloon cell melanoma, 36
Basal cell carcinomas (BCC), 15, 20
Basomelanocytic tumor, 36
Basosquamous melanoma, 36
Benign and small nevomelanocytic cells, 142
Binimetinib, 45

Blow dryers, 24
Blue nevus-like melanoma and melanoma arising in blue nevus, 35
Bowel metastasis, 185
BRAF, 45, 46, 55
BRAF-v600e mutations, negative for, 32
BRCA1 Associated Protein 1 (BAP1), 44
Breslow thickness, 32, 54, 69
Bullous acantholytic melanoma, 36, 42

C

Cervical lymphadenectomy, 163
CGH/SNP assay, 54
Checkpoint inhibitors (CPI), 157, 175
Chronic lymphocytic leukemia (CLL), 2, 6
Cimiplimab, 47
Circulating tumor cells (ctDNA), 50, 51, 55
c-KIT, 46
Clear cell sarcoma, 37
Cobimetinib, 45
Combination targeted therapy using *BRAF* and *MEK* inhibitors, 175
Comparative genomic hybridization (CGH) arrays, 48
CompariSkin™, 24
Completion lymphadenectomy (CLND), 126
Cross sectional imaging, 98, 102, 105, 106 modalities, 96 upstaging, 100
Curettage and desiccation (C&D), 2
Cutaneous melanoma, 18, 19, 32, 73, 103 age, 74 histologic subtypes of, 15
Cutis rhomboidalis, 3

- Cytomorphology, 32
 Cytoreductive/debulking surgery, 178
 Cytotoxic chemotherapy, 119
 Cytotoxic T lymphocyte antigen-4 (CTLA-4), 157, 166
- D**
 Dabrafenib, 45
 DecisionDx-Melanoma Test™, 50
 Deep groin lymphadenectomy, 164
 Deep penetrating nevus-like melanoma, 35
 Depth of invasion, 68, 69
 Dermal melanoma, 35
 Dermatoscopes, 11
 Desmoplastic melanoma, 34, 73
 Diphenacyclone (DPCP), 117
 Disparity in melanoma, 17, 18
 Disseminated disease, 178
 Distant melanoma metastases, 183
 Durvalumab, 47
 Dyscohesive malignant melanoma, 36
- E**
 Early detection, melanoma
 freckles, 3
 physical exam findings, 9–11
 risk factors for melanoma, 2, 4–9
 atypical nevi, 4
 CDKN2A mutation, 7, 8
 chronic lymphocytic leukemia, 6
 genetic testing, guideline for, 9
 hereditary cancer syndromes, 8, 11
 HIV, 7
 MC1R mutation, 4
 moles, 4
 personal history, 6
 populations at, 6
 positive family history, 9
 TNFi, 7
 rule of three, 11
 skin cancer screening, 2
 total body skin examination, 1
 Early stage disease, 98, 99
 Effective systemic therapy (EST), 176
 Elective LN dissection (ELND), 125
 Encorafenib, 45
 Enzyme-linked immunosorbent assays (ELISA), 51
 Epidemiology, 62, 63
 Epithelioid melanoma, 34
 Excisional biopsy for diagnosis, 162
- F**
 Familial atypical mole and malignant melanoma (FAMMM) syndrome, 4
 FDG PET/CT detection of cerebral melanoma metastases, 100
 Fine needle aspiration, 39
 Fluorescence in situ hybridization (FISH), 48, 49
 assay, 30, 50
 probes, 31
 5-fluorouracil, 2
 Follicular melanoma, 38
 French Group of Research on Malignant Melanoma, 113
- G**
 Genetic sequencing, 8
 Granular cell melanoma, 36
 Granulocyte-macrophage colony-stimulating factor (GM-CSF), 118
- H**
 Hematoxylin-eosin (H&E) staining, 140
 Hereditary cancer syndrome, 8, 11
 High resolution ultrasound (US), 90
 histopathology, 90
 normal and abnormal lymph nodes, 90–91
 primary assessment, 90
 simple excision biopsy, 90
 Histopathology of epithelioid and spindled melanocytes, 30
 HMB-45, 42
 Human immunovirus (HIV), 7
 Hyperkeratotic dark brown plaque, 16
 Hypomelanotic/amelanotic melanoma, 10
- I**
 IGF-1R signaling network, 45
 Imiquimod, 2, 117
 Immune checkpoint inhibitor (ICI)
 therapy, 47, 119
 Immune checkpoints, 46, 47, 157
 Immune therapy, 167, 173
 Immunohistochemistry (IHC) analysis, 140
 diagnostic, 39, 41–44
 prognostic and therapeutic
 BRAF, 45, 46
 c-KIT, 46
 IGF-1R signaling network, 45
 immune checkpoints, 46, 47
 MEK, 45

Incidence, melanoma, 62, 63
 Inguinal dissection, 155
 Interferon- α , 166
 Interleukin-2 (IL-2) Injections, 118
 Intralesional Injections, 117–119
 Intralesional therapy with oncolytics, 167
 Invasive melanoma, 62, 63, 69
 Invisible melanoma, 34
 Ipilimumab, 16, 47

K

Ki-67, 44

L

Laboratory evaluation of melanoma
 cytological atypia of dermal melanocytes, 30
 FISH assay, 30
 FISH probes, 31
 histopathologic diagnosis, 31
 histopathology, 32, 39
 Breslow thickness, 32, 39
 bullous acantholytic melanoma, 42
 epithelioid and spindled melanocytes, 30
 fine needle aspiration, 39
 histologic regression, 41
 lymphovascular invasion, 41
 mitotic figure, 40
 myxoid melanoma, 43
 overlying ulceration, 40
 rhabdoid melanoma, 42
 subtypes, 32–39
 tissue biopsy, 32
 immunohistochemistry (*see* Immunohistochemistry)
 liquid (serologic) biomarkers, 50–52
 molecular assays
 CGH/SNP arrays, 48
 FISH, 48, 49
 mutational load, 53
 RNA-base gene expression profiling, 49, 50
 sentinel lymph node biopsy, 32, 53, 54
 Lactate dehydrogenase (LDH), 51, 52, 76
 Larger subcapsular metastases, 92
 Later stage disease, 100
 Lentiginous melanoma on the sun-damaged skin of the elderly (LME), 33
 Lentigo maligna melanoma (LMM), 15, 32, 33, 115, 116
 Lichenoid keratosis-like melanoma, 38

Liquid (serologic) biomarkers, 50–52
 Liquid biopsies, 50
 Liver metastasis, 184
 Long noncoding RNA (lncRNA), 52
 Lymph node biopsy, 2
 Lymph node dissection, 152, 154, 155
 Lymph node infiltration by melanoma metastasis, 91
 Lymph node involvement, 115
 Lymphadenectomies, 165
 Lymphatic invasion, 74
 Lymphatic mapping with sentinel lymph node biopsy, 150
 Lymphoscintigraphy
 left forearm melanoma, 99
 technique, 85, 87
 and tracer injection, 136–138
 Lymphovascular invasion, 41

M

M1a disease, 183, 184
 M1b disease, 184
 M1c disease, 184, 185
 M1d disease, 185, 186
 Macrophages, 142
 Macroscopic metastasis, 89
 Malignant blue nevus, 35
 Management, 24
 Medicaid, 18
 Medical therapy, 157
 Medicare, 18
 MEK, 45
 Melan-A (MART-1), 42
 Melanoma >4 mm in depth, 115
 Melanoma in situ, 114
 Melanoma inhibitory activity protein (MIA), 76
 Melanoma of soft parts, 37
 Melanoma prevention, 23, 24
 Melanoma specific survival (MSS), 69
 Melanoma with aberrant phenotype, 39
 Melanoma with clear cells, 36
 Melanoma with plasmacytic features, 38
 Melanomas 1–2 mm in depth, 115
 Messenger-RNA (mRNA), 77
 Metastasectomy
 contemporary studies, 175
 disease control after surgical resection, 180
 historical studies, 174
 for melanoma, 173, 176
 morbidity, 180, 181
 patient selection, 176, 178, 180–182

- Metastatic melanoma, 76
 Micromelanoma, 36
 Microphthalmia transcription factor (Mitf), 43
 MicroRNA (miRNA), 52
 Miiskin™, 24
 Minimal deviation melanoma, 35
 Minimally invasive technique for groin lymphadenectomy, 165
 Mitogen-activated protein kinase pathway (MAPK), 45
 Mitotic figure, 40
 Mitotic rate, 71
 Mole mapping, 11
 MoleMapper™, 24
 Monster melanoma, 36
 Multicenter Selective Lymphadenectomy Trial (MSLT-I), 126, 127, 173
 Multicenter Selective Lymphadenectomy Trial (MSLT-II), 151, 154, 155
 Multinucleated cell melanoma, 36
 Mutational load, 53
 Myriad MyPath Melanoma Gene™, 50
 Myxoid melanoma, 43
- N**
 NeoSite™ melanoma, 30
 Nested melanoma of the elderly, 33
 Neurotropic melanoma and melanoma with neural differentiation, 34
 Neurotropic melanomas, 74
 Neurotropism, 74
 Nevi, 4
 Nevoid melanoma, 35
 Nevus association, 74
 Next-generation sequencing (NGS), 46, 47, 53
 Nivolumab, 47
 Nodal staging practices, 112
 Node field dissection, 96
 Nodular growth pattern, 73
 Nodular melanoma, 15, 33
 Non-melanoma skin cancer (NMSC), 20
- O**
 Oligometastatic disease, 172, 179
 Operative primary melanoma treatment, 112–115
 Osteocartilaginous melanoma, 37
 Overlying ulceration, 40
- P**
 Palpable parotid lymph node, 163–166
 Palpation of popliteal fossa, 161
 Pembrolizumab, 47, 52
 Pigmented epithelioid melanocytoma, 37
 Pigmented Lesion Assay™ (DermTech), 50
 Pigment-synthesizing melanoma, 37
 Plasmacytoid melanoma, 38
 Plexiform melanoma, 35
 Poikiloderma, 3
 Polypoid melanoma, 35
 Post treatment surveillance, 105, 106
 Posterior scalp melanoma, 75, 86
 Pre-operative lymphoscintigraphy, 83
 Primary dermal melanomas, 73
 Primary melanoma, diagnosis, 24
 Prognostic factors in melanoma
 age, 74, 75
 anatomical location, 75, 76
 conditional survival, 77
 depth of invasion, 68, 69
 gender, 75
 growth phase and melanoma subtypes, 72, 73
 lymphatic invasion and angiotropism, 74
 marital status, 75
 mitotic rate, 71
 molecular markers, 77
 neurotropism, 74
 nevus association, 74
 regression, 73
 tumor derived markers, 76
 tumor-infiltrating lymphocytes, 73, 74
 ulceration, 71
 Programed death-1 (PD-1), 157
 Programmed death ligand 1 (PD-L1), 47, 157
 Pseudoglandular melanoma, 37
 Pseudolipoblastic melanoma, 36
 PV-10, 119
- Q**
 Quantitative-PCR (qPCR), 51
 Quantitative reverse transcription polymerase chain reaction (qRT-PCR), 49, 50
- R**
 Race, 16–18, 20
 Radiation therapy (RT), melanoma, 2, 119, 156
 Radioguided occult lesion localization (ROLL), 101
 Radiolabeled colloid, 137, 143
 Real-time quantitative-PCR (qPCR), 51
 Regional lymph node (LN), 125
 Regional lymphadenectomy

- morbidity, 165
 - radiation therapy, 166
- Regressing melanoma, 34
- Regression, 73
- Response evaluation criteria in solid tumors (RECIST) criteria, 102, 103, 105
- Reverse transcriptase polymerase chain reaction (RT-PCR), 51, 143
- Rhabdoid melanoma, 37, 42
- Risk factors for melanoma, 2, 4, 5, 8
 - atypical nevi, 4
 - CDKN2A* mutation, 7, 8
 - chronic lymphocytic leukemia, 6
 - environmental factors, 21
 - genetic predisposition/family history, 20, 21
 - genetic testing, guidelines for, 9
 - hereditary cancer syndromes, 8
 - HIV, 7
 - MC1R* mutation, 4
 - moles, 4
 - personal medical history, 6, 20
 - phenotypic features, 18–20
 - populations at, 6
 - positive family history, 9
 - TNFi, 7
- RNA-base gene expression profiling, 49, 50
- Rose Bengal, 119
- Royal Marsden Melanoma Unit, 176

- S**
- Sarcomatoid melanoma, 37
- Screening of melanoma, 21, 23
- Sebocyte-like melanoma, 36
- Sentinel lymph node biopsy (SLN) biopsy, 32, 49, 53, 54, 83
 - blue-stained lymphatics and gamma probe, 139
 - Breslow thickness, 135
 - gamma probe, 138
 - guideline recommendations, 127, 129
 - intermediate-thickness and thick melanomas, 129, 134
 - lymphatic mapping, 139
 - multivariable analyses of clinicopathologic characteristics, 131–134
 - multivariable analyses of survival outcomes, 130
 - National guidelines for patient selection, 128
 - pathologic investigation, 140
 - positivity, 106
 - preoperative lymphoscintigram, 136
 - radiotracer uptake, 138
 - regional lymph node basins, 94, 95
 - tissue preservation, 140
 - truncal and extremity locations, 139
- Sentinel node metastasis, 135, 150, 151, 153
- Signet ring cell melanoma, 36
- Single nucleotide polymorphism (SNP) arrays, 48
- Small bowel metastasis, 185
- Small cell melanoma, 36
- Small particle radiocolloids, 85
- Small subcapsular metastasis, 92
- Society of Surgical Oncology (SSO), 127
- Solid organ transplant recipients (SOTR), 6
- Specimen staining and tumor burden assessment, 141, 142
- Spindle cell melanoma, 34
- Spitzoid melanoma, 35
- Squamomelanocytic tumor, 36
- Squamous cell carcinomas (SCC), 20
- SRY-related HMG-Box gene 10 protein (SOX10), 43, 54
- Stage IV melanoma
 - clinicopathologic characteristics, 179
 - colon mass, 172
 - cytotoxic chemotherapy, 173
 - diagnosis, 172
 - disease progression, 173
 - disease-free interval, 180, 186
 - immune-modulating agents, 173
 - isolated non-responding lesions, 176
 - M1a, 172
 - M1b, 172
 - M1d disease, 172
 - palliative procedures, 176
 - patient selection, 173
 - pre-/post-operative use of systemic therapy, 181
 - prognostic and morbidity considerations, 181
 - selective resection of treatment-resistant sites, 183
 - staging, 178
 - targeted therapies and immunotherapy, 173
 - treatment approach, 177
 - tumor biology, 176
 - tumor volume doubling time, 180
 - up-front surgery, 181
- Staging, 63–68
- Superficial lymphadenectomy, 164
- Superficial spreading melanoma, 15, 33
- Surgical lymphadenectomy, 163, 168

Surveillance FDG-PET/CT scan, 101
 Swedish Melanoma Study Group, 113
 Syringotropic melanoma, 38
 Systemic staging, distant metastases, 162, 163

T

Talimogene Laherparepvec (T-VEC)
 injections, 118
 Targeted BRAF/MEK therapy, 119
 Targeted therapy, 157, 167
 Tissue biopsy, 32
 Tissue diagnosis of regional disease, 162
 TNF-alpha inhibitors (TNFi), 7
 Total body skin examination (TBSE), 1, 10, 21
 Trametinib, 45
 Tremelimumab, 47
 Tumor biology, 180
 Tumor derived markers, 76
 Tumor factors, 136
 Tumor invasion, 16
 Tumor mutation burden (TMB), *see*
 Mutational load
 Tumor, node, and metastasis (TNM) staging
 system, 63, 64
 Tumor-infiltrating lymphocytes (TILs), 73, 74
 Tyrosinase mRNA expression, 43

U

Ugly duckling sign, 10
 Ulceration, 32, 71
 Ultraviolet light, 21
 United Kingdom Melanoma Study Group
 trial, 113
 United States Preventive Services Task Force
 (USPTF), 1, 21

V

Vemurafenib, 45

W

Wide excision, 112, 116, 120
 Areas of Uncertainty, 114–115
 clinical vs. pathologic margins, 114
 disease-free survival, 113
 local/general anesthesia, 112
 prognostic factor, 114
 skin grafting, 113
 Wide local excision (WLE), 88, 89, 126
 World Health Organization Melanoma
 Group, 113